Healthcare & Life Sciences
Pharma, medical devices, care delivery, diagnostics, and health services. This page compares reported financial scale with the customer needs and operating signals that shape sector performance.
- Companies
- 121
- Average revenue
- $31.2B
- Average margin
- 4.2%
- Average growth
- 10.8%
What this industry is really competing to solve
Demand emerges when patients and professionals need better outcomes with less risk, pain, delay, or uncertainty. The deeper motives are survival, safety, dignity, autonomy, and hope. This is why the competitive set extends beyond companies with the same industry code.
Customers can also choose standard of care, generics, alternative therapies, watchful waiting, prevention, and non-treatment. Industry growth becomes durable only when companies make the desired progress easier than those alternatives.
How demand becomes profit and cash
The common mechanism is turning clinical evidence, access, adherence, and professional trust into treated patients and durable economics. Across the industry, the decisive investment question is whether research, capacity, and access investment expands treated demand before patent, reimbursement, or safety risk erodes value.
Average operating profit is $2.1B, but the spread between leaders and laggards matters more than the average alone. Compare scale, margin, growth, and the leading indicators together.
Healthcare & Life Sciences companies
| Company | Revenue | Operating profit | Margin | Growth |
|---|---|---|---|---|
| UnitedHealth Group UNH | $447.6B | $19B | 4.2% | +11.8% |
| McKesson MCK | $403.4B | $6.2B | 1.5% | +12.4% |
| CVS Health CVS | $402.1B | $4.7B | 1.2% | +7.8% |
| Cencora COR | $321.3B | $2.6B | 0.8% | +9.3% |
| The Cigna Group CI | $274.9B | $9.2B | 3.3% | +11.2% |
| Cardinal Health CAH | $222.6B | $2.3B | 1.0% | -1.9% |
| Elevance Health ELV | $199.1B | $5.7B | 2.8% | +12.5% |
| Centene CNC | $194.8B | -$7.6B | -3.9% | +19.4% |
| Humana HUM | $129.7B | $2.7B | 2.1% | +10.1% |
| Johnson & Johnson JNJ | $94.2B | $26.8B | 28.5% | +6.0% |
| HCA Healthcare HCA | $75.6B | $6.8B | 9.0% | +7.1% |
| Eli Lilly LLY | $65.2B | $25.7B | 39.5% | +44.7% |
| Merck & Co. MRK | $65B | $18.3B | 28.1% | +1.3% |
| Pfizer PFE | $62.6B | $7.5B | 12.0% | -1.6% |
| AbbVie ABBV | $61.2B | $15.1B | 24.6% | +8.6% |
| Bristol Myers Squibb BMY | $48.2B | $7.1B | 14.6% | -0.2% |
| Molina Healthcare MOH | $45.4B | $781M | 1.7% | +11.7% |
| Thermo Fisher Scientific TMO | $44.6B | $7.7B | 17.4% | +3.9% |
| Abbott Laboratories ABT | $44.3B | $8.1B | 18.2% | +5.7% |
| Amgen AMGN | $36.8B | $9.1B | 24.7% | +10.0% |
| Medtronic MDT | $36.4B | $6.5B | 17.8% | +8.4% |
| Gilead Sciences GILD | $29.4B | $10B | 34.0% | +2.4% |
| Stryker SYK | $25.1B | $4.9B | 19.5% | +11.2% |
| Danaher DHR | $24.6B | $4.7B | 19.1% | +2.9% |
| Becton Dickinson BDX | $21.8B | $2.6B | 11.8% | +8.2% |
| GE HealthCare Technologies GEHC | $20.6B | $2.8B | 13.4% | +4.8% |
| Boston Scientific BSX | $20.1B | $3.6B | 18.0% | +19.9% |
| IQVIA IQV | $16.3B | $2.2B | 13.4% | +5.9% |
| Regeneron Pharmaceuticals REGN | $14.3B | $3.6B | 24.9% | +1.0% |
| Viatris VTRS | $14.3B | -$2.7B | -18.7% | -3.0% |
| Labcorp LH | $14B | $1.4B | 9.9% | +7.2% |
| DaVita DVA | $13.6B | $2B | 15.0% | +6.5% |
| Henry Schein HSIC | $13.2B | $653M | 5.0% | +4.0% |
| Community Health Systems CYH | $12.5B | $1.5B | 11.9% | -1.2% |
| Vertex Pharmaceuticals VRTX | $12B | $4.2B | 34.8% | +8.9% |
| Baxter International BAX | $11.2B | -$957M | -8.5% | +5.7% |
| Quest Diagnostics DGX | $11B | $1.6B | 14.1% | +11.8% |
| Intuitive Surgical ISRG | $10.1B | $2.9B | 29.3% | +20.5% |
| Biogen BIIB | $9.9B | $1.3B | 13.1% | +2.2% |
| Zoetis ZTS | $9.5B | $3.4B | 35.5% | +2.3% |
| Zimmer Biomet ZBH | $8.2B | $1.1B | 13.3% | +7.2% |
| Agilent Technologies A | $6.9B | $1.5B | 21.3% | +6.7% |
| Organon OGN | $6.2B | $425M | 6.8% | -2.9% |
| Edwards Lifesciences EW | $6.1B | $1.3B | 20.8% | +11.5% |
| STERIS STE | $5.9B | $1.1B | 18.6% | +8.7% |
| Encompass Health EHC | $5.9B | $759M | 12.8% | +10.5% |
| Option Care Health OPCH | $5.7B | $338M | 6.0% | +13.0% |
| ResMed RMD | $5.1B | $1.7B | 32.7% | +9.8% |
